Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a catechol-O-methyl transferase inhibitor
Authors:
- Cletus U IwuagwuCICletus U Iwuagwu
- David RileyDRDavid Riley
- Robert A BonomoRBRobert A Bonomo
- 1 April 2000
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 108 (6) , 517-518
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-CarbidopaArchives of Neurology, 1998
- Effect of Tolcapone on Plasma Levodopa Concentrations after Coadministration with Levodopa/Carbidopa to Healthy VolunteersClinical Neuropharmacology, 1997
- Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*Clinical Pharmacology & Therapeutics, 1997
- Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatmentNeurology, 1997
- Emerging Treatments in Parkinson's DiseaseEuropean Neurology, 1997
- Neuroleptic malignant syndrome: review and analysis of 115 casesBiological Psychiatry, 1987
- Neuroleptic Malignant SyndromeNew England Journal of Medicine, 1985
- Neuroleptic Malignant SyndromeClinical Neuropharmacology, 1984
- Neuroleptic Malignant Syndrome-like State Following a Withdrawal of Antiparkinsonian DrugsJournal of Nervous & Mental Disease, 1981